Chemotherapy often destroys much of the immunity your previous vaccinations built. The damage can be severe: in one study of breast cancer patients, the immune cells most responsible for making antibodies dropped to about 5 percent of their pre-treatment levels, and antibody levels against diseases like tetanus and pneumococcal infection fell significantly and had not bounced back even nine months later.1PubMed Central. Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer The short version is that many cancer patients need to be revaccinated after finishing treatment, essentially restarting parts of their childhood immunization schedule as adults.
Why Chemotherapy Damages Vaccine Immunity
Vaccines work by training your immune system to recognize a specific germ. The cells that carry that memory fall into a few categories. Some are long-lived plasma cells that quietly churn out antibodies for years or even decades. Others are memory B cells and T cells that spring into action if the pathogen shows up again. Chemotherapy drugs are designed to kill rapidly dividing cells, and while they target cancer, they also hammer the immune system’s cellular workforce. B cells, which are the precursors to antibody-producing cells, take a particularly hard hit.
In breast cancer patients treated with standard chemotherapy regimens, B cells fell to just 5.4 percent of their pre-treatment numbers two weeks after treatment. T cells and natural killer cells also dropped, though less dramatically. While all of these cell populations started to recover over subsequent months, B cells and a key subset of T cells called CD4+ cells were still significantly below their starting levels nine months after chemotherapy ended.1PubMed Central. Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer This sluggish recovery helps explain why the protection from old vaccines can vanish: even after new immune cells eventually grow back, many of the memory cells that “remembered” past vaccinations are gone.
One reason this is so stubborn is that long-lived plasma cells, the ones that keep producing antibodies for years after a vaccination, are notoriously hard to replace once destroyed. These cells can survive for decades under normal circumstances, but they are also difficult to regenerate from scratch. Therapeutic strategies aimed at targeting them have largely struggled precisely because of how unusual and specialized these cells are.2PubMed Central. On the road to eliminating long-lived plasma cells-“are we there yet?” When chemotherapy wipes them out, the antibodies they were producing simply stop being made, and the body has no quick way to restart that production without re-exposure to the vaccine antigen.
Which Vaccinations Are Most Vulnerable
The damage is not limited to one or two vaccines. Studies consistently show that protection against a broad range of vaccine-preventable diseases erodes after chemotherapy. In children treated for acute lymphoblastic leukemia, researchers found a significantly higher rate of negative titers for hepatitis B, varicella (chickenpox), MMR (measles, mumps, rubella), and DTaP (diphtheria, tetanus, pertussis) compared to the general pediatric population.3Blood. Patterns of Vaccine Titers after Childhood Leukemia Treatment In adult breast cancer patients, both anti-pneumococcal and anti-tetanus antibodies fell significantly and showed no sign of recovering on their own during the follow-up period.1PubMed Central. Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer
After stem cell transplantation, which involves even more aggressive immune destruction than standard chemotherapy, antibody levels against tetanus, polio, measles, mumps, and rubella decline within one to ten years if the patient is not revaccinated.4PubMed Central. Vaccination of hematopoietic stem cell transplantation recipients: perspective in Korea The pattern is clear across tumor types and age groups: chemotherapy does not selectively erase protection against one disease while sparing another. It tends to knock down immunity broadly.
Children Face an Especially Tricky Situation
When an adult loses vaccine immunity, the inconvenience is real but the solution is relatively straightforward: get the shots again. For children, the picture is more complicated. A child treated for leukemia at age four may have received only some of their scheduled vaccinations before diagnosis. Treatment can last two to three years, during which live vaccines are off-limits. By the time treatment ends, the child may have lost protection from the vaccines they did receive and still be behind on the ones they missed.
Research confirms this concern. Children who completed treatment for acute leukemia showed elevated rates of lost immunity across hepatitis B, varicella, MMR, and DTaP.3Blood. Patterns of Vaccine Titers after Childhood Leukemia Treatment Clinical guidelines have recognized for years that a structured revaccination schedule is warranted after leukemia treatment, given the documented decrease in vaccine-specific antibody and increased susceptibility to vaccine-preventable diseases.5Clinical Infectious Diseases. Revaccination of Children after Completion of Standard Chemotherapy for Acute Leukemia Pediatric oncology centers typically direct patients toward revaccination about six months after finishing treatment, tailoring the schedule based on what vaccines were given before diagnosis and which antibody levels have dropped to unprotective levels.6PubMed Central. Revaccination in Pediatric Oncology Patients: One Center Experience
Getting Vaccinated During Active Chemotherapy
You might wonder whether it is worth getting vaccinated while still receiving chemotherapy rather than waiting until treatment is over. The answer depends on the vaccine and the urgency. Inactivated vaccines like the flu shot are generally considered safe during treatment, but they do not work nearly as well. One review of influenza vaccination in cancer patients found that immune responses were consistently weaker in people receiving chemotherapy: only about 17 to 52 percent achieved a meaningful antibody rise, compared with 50 to 83 percent in patients who had finished chemo and 67 to 100 percent in healthy individuals.7PubMed Central. Influenza vaccination in cancer patients undergoing systemic therapy
A similar story emerged during the COVID-19 pandemic. Among cancer patients receiving chemotherapy or chemoimmunotherapy who got two doses of an mRNA vaccine, antibody levels were significantly lower than in people without cancer, and roughly 7 percent of cancer patients developed only low levels of neutralizing antibodies.8PubMed Central. Impact of chemotherapy and/or immunotherapy on neutralizing antibody response to SARS-CoV-2 mRNA-1237 vaccine in patients with solid tumors So while receiving an inactivated vaccine during chemo is not dangerous, the protection you get is substantially reduced. For seasonal threats like influenza, oncologists still recommend the shot during treatment because even partial protection is better than none. But the expectation is that the response will be blunted.
Live Vaccines Are a Different Story Entirely
Live vaccines contain weakened but still functional versions of a virus or bacterium. In a person with a healthy immune system, these weakened organisms trigger a strong immune response without causing disease. But in someone whose immune system has been suppressed by chemotherapy, those weakened organisms can actually cause the disease they were meant to prevent. This is why live vaccines, including MMR, varicella, and the live oral polio vaccine, are strictly off-limits during active chemotherapy and for a period afterward.9PubMed Central. Vaccination in patients with immunosuppression
The waiting period before live vaccines can safely be given again depends on how much the immune system has recovered. Most guidelines recommend waiting at least three to six months after immunosuppressive therapy ends, though the exact timing can vary based on the type of treatment and the patient’s blood counts. This is one of the reasons revaccination cannot just start the day chemotherapy finishes.
Should Doctors Check Your Titers or Just Revaccinate?
A reasonable question after chemotherapy is whether your doctor should test your blood for remaining antibody levels (called titers) before deciding which vaccines to repeat. In theory, this makes sense: why revaccinate against measles if your antibodies are still at protective levels? In practice, the evidence suggests that blanket revaccination is more reliable than the test-and-decide approach.
A retrospective study of pediatric oncology patients found that the vast majority had at least one titer checked after chemotherapy, but the results were inconsistent enough that the researchers concluded checking titers was not recommended. Their advice was blunt: providers should assume loss of immunity and proceed with revaccination.10PubMed. Post-Chemotherapy Titer Status and Need for Revaccination After Treatment for Childhood Cancer The reasoning is that a titer may look adequate at one point in time but continue to fade, and the cost and complexity of interpreting incomplete titer panels often delays revaccination without improving outcomes. This recommendation does not apply to every clinical scenario, but it has shaped how many oncology practices handle post-treatment revaccination.
B-Cell-Depleting Therapies Hit Even Harder
Standard chemotherapy damages the immune system broadly, but a class of drugs known as B-cell-depleting therapies, most famously rituximab, targets the antibody-producing arm of immunity with surgical precision. Rituximab is used in certain lymphomas, autoimmune diseases, and other conditions. It works by eliminating B cells almost entirely, which is helpful for the disease being treated but devastating for vaccine responses.
Research on rituximab showed that antibody responses to vaccines were severely reduced during the period when B cells were depleted. However, there was a silver lining: once B cells recovered, patients who were revaccinated showed responses that were qualitatively and quantitatively similar to normal primary vaccination responses.11Journal of Allergy and Clinical Immunology. Effect of rituximab on human in vivo antibody immune responses In other words, the immune system was not permanently broken by these drugs. It was temporarily emptied. Once the cells came back, the system could learn again from scratch, though any previous memory was likely gone.
The American Society of Clinical Oncology now specifically calls out B-cell-depleting therapy, alongside stem cell transplantation and CAR T-cell therapy, as treatments after which revaccination should be a formal part of the care plan.12PubMed Central. Vaccination of Adults With Cancer: ASCO Guideline Timing matters here more than with standard chemotherapy because B-cell recovery after rituximab can take six months to a year or longer. Vaccinating before B cells are back is essentially wasted effort.
When the Cancer Itself Suppresses Immunity
An underappreciated wrinkle is that some cancers damage the immune system independently of any treatment. This is especially true of blood cancers. Patients with chronic lymphocytic leukemia or multiple myeloma often have weakened immune function as a direct result of the disease, which compounds the immune damage from chemotherapy. These patients face a heightened risk of serious infections that persists even years after treatment ends.13PubMed Central. Secondary Immunodeficiency in Hematological Malignancies: Focus on Multiple Myeloma and Chronic Lymphocytic Leukemia
For these patients, vaccination is both more important and less likely to work well. Their underlying disease makes them more susceptible to infections, but it also blunts their ability to respond to vaccines. The clinical challenge is navigating this catch-22, which is why oncologists and infectious disease specialists increasingly collaborate on individualized vaccination plans rather than relying on one-size-fits-all schedules.
Protecting Yourself While Your Immune System Recovers
Between finishing chemotherapy and completing revaccination, there is a window of vulnerability. During this time, you are potentially unprotected against diseases you were vaccinated for years ago. One strategy that has gained traction is what researchers call “cocoon vaccination,” where the people around you, household contacts, family members, caregivers, get vaccinated to create a buffer zone of immunity. A study examining this approach for influenza in cancer patients found that vaccinating both the patients and their close contacts offered a layer of protection against infection.14PubMed Central. Cocoon vaccination for influenza in patients with a solid tumor: a retrospective study
This strategy is most commonly discussed for infants who are too young to be vaccinated, but it applies equally well to immunocompromised adults. If everyone in your household is up to date on their flu shots and COVID boosters, the odds of a virus making it to you drop considerably. It is a practical step that does not require waiting for your own immune system to bounce back.
What COVID-19 Revealed About Cancer Patients and Vaccines
The pandemic became an unintentional large-scale experiment in how cancer patients respond to vaccines. Because COVID-19 vaccines were rolled out to billions of people in a short time, researchers had an unprecedented opportunity to track antibody responses across different populations. The results confirmed what smaller studies of flu and pneumococcal vaccines had long suggested, but with much larger datasets.
In one study tracking antibody levels in cancer patients after two doses of an mRNA vaccine, the average antibody level dropped from about 912 units shortly after the second dose to 378 at three months and 165 at six months. A third dose produced a dramatic boost, pushing levels to roughly 1,903 units, which was two to five times higher than the peak after the second dose. But the rate of decline varied starkly by treatment type. Patients on certain drugs, like BTK inhibitors and active chemotherapy, became seronegative, meaning they had no detectable antibodies, as early as two months after their second vaccination. Patients not on active treatment held up much better and could have waited up to a year before needing a booster.15Cell Press (Cancer Cell). Waning of SARS-CoV-2 antibody responses and the need for a third and fourth vaccine dose in patients with cancer
These findings reinforced a practical message: the standard vaccine schedule designed for healthy people does not necessarily work for cancer patients. More frequent doses and careful monitoring of treatment timing may be needed. Several professional organizations have updated their guidance accordingly.
Why Many Cancer Survivors Still Do Not Get Revaccinated
Despite the clear evidence that chemotherapy erodes vaccine immunity, revaccination rates among cancer survivors remain lower than they should be. A scoping review of vaccine uptake among post-treatment cancer survivors found significant gaps in coverage and highlighted the absence of widely adopted clinical guidelines that specifically address vaccination in this population.16PubMed Central. Vaccination uptake among post-treatment cancer survivors: A multi-vaccine scoping review Part of the problem is that the transition from active treatment to survivorship care can be chaotic. Patients are managing follow-up scans, lingering side effects, and emotional recovery. Revaccination can slip through the cracks unless it is explicitly built into the survivorship care plan.
The ASCO guideline on vaccination of adults with cancer now emphasizes that optimizing vaccination status should be a key element of care, starting with documenting a patient’s vaccination history at the very first visit.12PubMed Central. Vaccination of Adults With Cancer: ASCO Guideline This is a shift from treating revaccination as an afterthought to treating it as a core part of cancer care. If you are a cancer survivor and no one has talked to you about your vaccination status, bring it up. The evidence is clear enough that the question is not whether you need revaccination, but which vaccines and when.
The Recovery Timeline Is Not a Single Number
One of the frustrations for patients is that there is no single answer to “when will my immune system be back to normal?” The timeline depends on what type of chemotherapy you received, how many cycles, whether B-cell-depleting drugs were involved, and your individual biology. B cells tend to recover faster than the long-lived plasma cells that produce sustained antibody levels. You might have normal-looking blood counts months before your functional immune memory is rebuilt.
For standard chemotherapy, most pediatric oncology centers begin the revaccination process about six months after treatment ends.6PubMed Central. Revaccination in Pediatric Oncology Patients: One Center Experience After stem cell transplant, the timeline is typically longer and the revaccination schedule more comprehensive, sometimes resembling a full infant vaccination series given to an adult. After rituximab or similar B-cell-depleting agents, vaccination is generally delayed until B cells are measurably recovering, which can take six months to a year or more after the last dose.11Journal of Allergy and Clinical Immunology. Effect of rituximab on human in vivo antibody immune responses The encouraging finding from rituximab studies is that once B cells do return, the immune system can mount normal vaccine responses again, which means the damage is temporary rather than permanent, even if “temporary” stretches across many months.